Valneva (NASDAQ:VALN) Releases Quarterly Earnings Results, Misses Estimates By $0.32 EPS

Valneva (NASDAQ:VALN) issued its quarterly earnings data on Wednesday. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32), Zacks reports. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%.

Valneva Stock Up 4.9 %

Shares of VALN traded up $0.33 during midday trading on Thursday, hitting $7.06. The company had a trading volume of 9,807 shares, compared to its average volume of 25,911. The stock has a market cap of $573.78 million, a price-to-earnings ratio of -55.00 and a beta of 1.93. The company’s 50 day moving average price is $6.24 and its 200 day moving average price is $5.60. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. Valneva has a 52 week low of $3.62 and a 52 week high of $9.50.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $17.00 target price on shares of Valneva in a research note on Friday, February 28th.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.